N/A N=408 Prostate Cancer Screening Trial Using Imaging
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=48 Prostate Cancer Detection Screening MRI Protocol
Prostate Cancer
Primary: Number of Participants With Any Grade or High Grade (Gleason Score 7 or Higher) Prostate Cancer as Measured by Histopathology — 11; 8 Participants
N/A N=24 Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Prostate Cancer · Magnetic Resonance Imaging · Target Lesion
Primary: Number of Participants With Clinically Significant Prostate Cancer — 6; 6 Participants
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
N/A N=95 Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging
Prostate Cancer
Primary: Micro-Ultrasound Detection of High Grade Prostate Cancer (Gleason Score ≥7) vs. Surgical Pathology — 38; 50 participants
N/A N=25 Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA
Prostate Cancer
Primary: Prostate Cancer Detection Within the Prostate Gland by Copper Cu 64 TP3805 PET — 25 Participants
Phase 3 N=19 Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
Prostate Adenocarcinoma
Primary: Uptake Value of C11-choline — 6.2 Ratio
N/A N=66 Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy
Patients With High-risk Prostate Cancer
Primary: Number of Participants With Circulating Tumor Cells in the Peripheral Blood — 60; 5 Participants
Phase 2 N=40 Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
Prostate Cancer
Primary: Compare the Biodistribution of 11C-acetate Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Tumor and Non Tumorous Regions of the Prostate — 4.4…
Phase 2 N=25 FACBC for Recurrent Prostate Cancer
Recurrent Prostate Cancer
Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants
Phase 4 N=383 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
Prostate Cancer
Primary: Pre/Post Ratio PSA Area Under the Curve (AUC) — 0.57; 0.61 Ratio
Phase 2 N=39 Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Prostate Cancer
Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc
N/A N=64 High Resolution MRI Study for Prostate Cancer
Prostate Cancer
Primary: Sensitivity and Specificity of High Resolution Versus Standard MRI in Identifying Adverse Histology — 75; 71; 84; 54.8 percent
N/A N=130 Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer
Prostatic Neoplasms
Primary: Number of Prostate Cancer Diagnoses in MRI and no MRI Groups — 34; 34 participants
Phase 2 N=24 Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
Prostate Cancer
Primary: Uptake and Retention of Eovist in Prostate Cancers — 2.01; 1.857; 2.52; 2.212 contrast enhancement ratio (CER) — p=0.0008
Phase 2 N=36 PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
Prostate Cancer
Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage
Phase 2 N=61 Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
Cancer
Primary: Cancer Detection Performance of FACBC PET/CT — 17; 22; 4; 14 Participants
Early Phase 1 N=116 18F-DCFBC PET/CT in Prostate Cancer
Prostatic Neoplasms · Prostate Cancer
Primary: Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites Detected by…
Phase 2 N=55 Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
Prostatic Neoplasm
Primary: Percentage of Subjects Whose Prostate Cancer Was Detected With Subharmonic Imaging — 24 Participants
N/A N=480 Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
Prostate Cancer Detection
Primary: Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases — 150.8; 239.6 ratio
Phase 2 N=18 A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
Prostate Cancer
Primary: Number of Lesions With Gleason Score ≥ 7 Identified by Ultrasound Molecular Imaging — 17; 8 number of lesions
N/A N=1 Prostate Cancer Screening in Men With Germline BRCA2 Mutations
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Phase 3 N=61 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Prostate Adenocarcinoma · PSA Failure · Recurrent Prostate Carcinoma
Primary: Confirmation of Prostate Cancer Recurrence by 68Ga-PSMA-11 PET/CT — 46; 15 Participants
Phase 2 N=17 Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Measurement of Sensitivity of DCFBC-PET as Determined by Agreement of PET/CT Detection of Metastatic Prostate Cancer With Conventional Imaging Modality (CIM) — 148; 170…
N/A N=106 Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy
Prostate Cancer
Primary: Accuracy of HM-MRI — 0.55 proportion of participants — p=0.02
Phase 3 N=165 FACBC Outcomes for Post Prostatectomy
Prostate Cancer
Primary: Failure-free Survival — 75.5; 63.0 Percentage of participants
N/A N=173 PET Scan in Treating Patients With Metastatic Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 91.6 weeks
Phase 2 N=20 PSMA Imaging of Localized Prostate Cancer
Prostate Cancer
Primary: The Number of Subjects With PSMA-positive (Prostate-specific Membrane Antigen) "Dominant" PC Lesion(s) Greater Than 5mm in Diameter, Whose Lesion(s) Have Been…
Phase 2 N=93 FACBC PET/CT for Recurrent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants
Phase 2 N=20 The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
Prostate Cancer · Prostate Cancer Metastatic
Primary: Number of Primary Prostate Lesions Detected on Early Dynamic 68Ga-PSMA-11 PET/CT Imaging — 24 lesions